Ohio State Navbar

News


An Up-and-Coming Superstar!


November 04, 2014

Ashley Rosko, MD, an assistant professor in the Division of Hematology at Ohio State and a member of the Cancer Control Program at the OSUCCC – James, has received one of five Young Investigator Awards presented by the National Comprehensive Cancer Network (NCCN) Foundation. The Foundation annually awards these grants – each worth $150,000 over two years – to young investigators at NCCN member institutions who are dedicated to advancing and discovering treatments for cancer, enhancing quality and improving education. The awardees submitted grant proposals that were reviewed by a multidisciplinary panel of oncology experts who judged them on several components, including scientific merit and study design. Dr. Rosko’s funded project is “NCCN Senior Adult Oncology: Myeloma Comprehensive Geriatric Assessment and Biomarkers of Aging Investigation.” The OSUCCC – James is a charter member of the NCCN, a not-for-profit alliance of 25 of the world’s leading cancer centers. The alliance is dedicated to improving the quality and effectiveness of care provided to patients with cancer. The rest of the story



Health Care Heroes Recognized - John C. Byrd, Honorable Mention


July 17, 2014

Columbus Business First recognized the honorees for its Health Care Heroes Awards during an event Thursday morning. The rest of the story



Ohio State Hematologist Regcognized Nationally


April 14, 2014

John Byrd has again received national scientific recognition for his translational research investigating use of the drug, ibrutinib, in the treatment of chronic lymphocytic leukemia, at the 2014 Clinical Research Forum’s third annual Top 10 Research Achievement Awards. Byrd is hematology division director and co-leader of the Leukemia Research Program at Ohio State’ Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute (OSUCCC – James.) The rest of the story



John C. Byrd, MD, Director of the Division of Hematology Honored


March 06, 2014

John C. Byrd, MD, director of the Division of Hematology at Ohio State and co-leader of the Leukemia Research Program at the OSUCCC – James, has been named associate editor of the journal Blood, which is the official publication of the American Society of Hematology (ASH) and one of the premier publications in the field. “This is truly an honor and a reflection of the high esteem that Dr. Byrd has earned in our academic discipline,” says Michael Grever, MD, professor and chair of the Department of Internal Medicine at Ohio State and co-leader of the Leukemia Research Program at the OSUCCC – James. “This well-deserved honor will reflect highly upon Ohio State and our comprehensive cancer center.” Byrd is a professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences at Ohio State, where he also holds the D. Warren Brown Designated Chair in Leukemia Research. The rest of the story



Study Identifies Possible Target For Future Brain Cancer Drugs


March 06, 2014

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at the OSUCCC – James. The findings were published in the journal Cancer Research. Robert Baiocchi, MD, PhD, associate professor of medicine at Ohio State and a hematologist at the OSUCCC – James, was co-corresponding author. The rest of the story



Register For The 2014 ASH Review


January 09, 2014

Kristie Blum, MD, an associate professor in the Division of Hematology at Ohio State and a member of the Molecular Biology and Cancer Genetics Program at the OSUCCC – James, will be the keynote speaker at Ohio State’s 2014 ASH Review, which will unfold from 7:30 a.m.-4 p.m. on Friday, Jan. 31, in Room 115 of the Biomedical Research Tower. Blum is an expert in novel therapies for lymphoma, particularly the targeted agent ibrutinib. The annual conference will provide a comprehensive review of advances in the biology, etiology, diagnosis, therapy and evidence-based management of blood cancers as presented at the 2013 American Society of Hematology (ASH) annual meeting held Dec. 7-10 in New Orleans. The ASH review is intended for primary care physicians, hematologists and oncologists, researchers, nurses and other healthcare professionals involved in hematology. There is no fee to attend, but registration is required at go.osu.edu/ASHREVIEW. Questions? Contact Katie Jones at katie.jones@osumc.edu of 366-5183. The rest of the story



AML Score That Combines Genetic and Epigenetic Changes May Help Guide Therapy


January 09, 2014

Currently, doctors use chromosome markers and gene mutations to determine the best treatment for a patient with acute myeloid leukemia (AML). But a new study suggests that a score based on seven mutated genes and the epigenetic changes that the researchers discovered were present might help guide treatment by identifying novel subsets of patients. The findings, published in the Journal of Clinical Oncology, come from a study led by researchers at the OSUCCC – James. Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser for the OSUCCC – James, was principal investigator for the study, and Guido Marcucci, MD, a professor in the Division of Hematology at Ohio State who also serves as associate director for translational research at the OSUCCC – James, was first author. The rest of the story



Study Confirms Target of Potent Chronic Leukemia Drug


January 09, 2014

A study led by researchers at the OSUCCC – James helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia. Amy Johnson, PhD, associate professor in the Division of Hematology and an OSUCCC – James researcher, was principal investigator for the study, which was published in the journal Blood. The rest of the story



Celebrate MMORE GALA, February 8, 2014


November 13, 2013

This wonderful evening includes fabulous appetizers and dinner, inspirational presentations, unique items in silent and live auctions, music and dancing. The rest of the story



Ohio State Saddened By Passing of Dr. Bertha Bouroncle


September 05, 2013

Ohio State Saddened By Passing of Dr. Bertha Bouroncle. Bertha A. Bouroncle, MD, a professor emerita of Internal Medicine at Ohio State who was the first to identify hairy cell leukemia and later helped develop an effective therapy for it, died Aug. 16 surrounded by family and friends at the Ross Heart Hospital. The rest of the story



Next